These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11028944)

  • 1. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects.
    Ahmed S; Sileno AP; deMeireles JC; Dua R; Pimplaskar HK; Xia WJ; Marinaro J; Langenback E; Matos FJ; Putcha L; Romeo VD; Behl CR
    Pharm Res; 2000 Aug; 17(8):974-7. PubMed ID: 11028944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness.
    Al-Ghananeem AM; Malkawi AH; Crooks PA
    Drug Dev Ind Pharm; 2007 May; 33(5):577-82. PubMed ID: 17520450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of scopolamine hydrobromide oral disintegrative microencapsule tablets in Beagle dogs determined with LC-MS/MS].
    Xia T; Liu DD; Shi LF; Hu JH
    Yao Xue Xue Bao; 2011 Aug; 46(8):951-4. PubMed ID: 22007521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of baseline human nasal pH and the effect of intranasally administered buffers.
    Washington N; Steele RJ; Jackson SJ; Bush D; Mason J; Gill DA; Pitt K; Rawlins DA
    Int J Pharm; 2000 Apr; 198(2):139-46. PubMed ID: 10767563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers.
    Stetina PM; Madai B; Kulemann V; Kirch W; Joukhadar C
    Int J Clin Pharmacol Ther; 2005 Mar; 43(3):134-9. PubMed ID: 15792397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers.
    Ebert U; Grossmann M; Oertel R; Gramatté T; Kirch W
    J Clin Pharmacol; 2001 Jan; 41(1):51-60. PubMed ID: 11144994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy.
    Cao SL; Zhang QZ; Jiang XG
    Acta Pharmacol Sin; 2007 Apr; 28(4):584-90. PubMed ID: 17376300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation pharmacokinetics of intranasal scopolamine gel formulation.
    Wu L; Boyd JL; Daniels V; Wang Z; Chow DS; Putcha L
    J Clin Pharmacol; 2015 Feb; 55(2):195-203. PubMed ID: 25187210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects.
    Ebert U; Oertel R; Kirch W
    Int J Clin Pharmacol Ther; 2000 Nov; 38(11):523-31. PubMed ID: 11097144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nasal absorption of growth hormone in normal subjects: studies with four different formulations.
    Laursen T; Ovesen P; Grandjean B; Jensen S; Jørgensen JO; Illum P; Christiansen JS
    Ann Pharmacother; 1994; 28(7-8):845-8. PubMed ID: 7949497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of intranasal scopolamine in normal subjects.
    Putcha L; Tietze KJ; Bourne DW; Parise CM; Hunter RP; Cintrón NM
    J Pharm Sci; 1996 Aug; 85(8):899-902. PubMed ID: 8863287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation).
    Nakade S; Komaba J; Ohno T; Kitagawa J; Furukawa K; Miyata Y
    Int J Clin Pharmacol Ther; 2008 Jan; 46(1):42-7. PubMed ID: 18218297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pH on sublingual absorption of oxycodone hydrochloride.
    Al-Ghananeem AM; Malkawi AH; Crooks PA
    AAPS PharmSciTech; 2006 Mar; 7(1):E163-E167. PubMed ID: 28290038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pH on sublingual absorption of oxycodone hydrochloride.
    Al-Ghananeem AM; Malkawi AH; Crooks PA
    AAPS PharmSciTech; 2006 Mar; 7(1):E23. PubMed ID: 16584154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects.
    Putcha L; Cintrón NM; Tsui J; Vanderploeg JM; Kramer WG
    Pharm Res; 1989 Jun; 6(6):481-5. PubMed ID: 2762223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.